A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
← catalyst calendarSponsored by Edgewise Therapeutics, Inc. (industry) · EWTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
25actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-26 | actual | When the study began enrolling |
| Primary completion | 2026-04-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-07 | actual | The whole study's end, after follow-up |
| First posted | 2026-01-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatic Impairment (HI)
Intervention
- Drug: EDG-7500
Primary outcomes
what the primary-completion date above is the date OFArea under the plasma concentration time-curve from time zero to the last measured concentration (AUC0-last)
measured Pre-dose to day 10
Area under the plasma concentration time-curve from time zero extrapolated to infinity (AUC0-inf)
measured Pre-dose to day 10
Maximum observed plasma concentration (Cmax)
measured Pre-dose to day 10
Permalink · EWTX's whole pipeline · Catalyst calendar · Every registered study · What changed